Omega-3 polyunsaturated fatty acid supplementation improves lipid metabolism and endothelial function by providing a beneficial eicosanoid-pattern in patients with acute myocardial infarction: A randomized, controlled trial
Meng Yuan,Yue Zhang,Tong Hua,Xiang-Li Liu,Tong Liu,Ru-Yu Yuan,Guang-Ping Li,Yi Zhu,Xu Zhang
DOI: https://doi.org/10.1016/j.clnu.2020.05.034
IF: 7.643
2021-02-01
Clinical Nutrition
Abstract:<h2 class="section-title u-h3 u-margin-l-top u-margin-xs-bottom">Summary</h2><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background and aims</h3><p>Omega-3 polyunsaturated fatty acid (ω-3 PUFA) have been reported to have beneficial cardiovascular effects, but its mechanism of protection against acute myocardial infarction (AMI) who are under guideline-based therapy is not fully understood. Here, we used a metabolomic approach to systematically analyze the eicosanoid metabolites induced by ω-3 PUFA supplementation and investigated the underlying mechanisms.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>Participants with AMI after successful percutaneous coronary intervention were randomized to 3 months of 2 g daily ω-3 PUFA and guideline-adjusted therapy (n=30, ω-3 therapy) or guideline-adjusted therapy alone (n=30, Usual therapy). Functional PUFA-derived eicosanoids in plasma were profiled by metabolomics. Clinical and laboratory tests were obtained before and 3 months after baseline and after the study therapy.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>By intent-to-treat analysis, the content of 11-HDoHE, 20-HDoHE and 16,17-EDP and that of epoxyeicosatetraenoic acids (EEQs), derived from docosahexaenoic acid and eicosapentaenoic acid, respectively, were significantly higher with ω-3 group than Usual therapy, whereas that of prostaglandin J2 (PGJ2) and leukotriene B4, derived from arachidonic acid, was significantly decreased. As compared with Usual therapy, ω-3 PUFA therapy significantly reduced levels of triglycerides (-6.3%, <em>P</em><0.05), apolipoprotein B (-4.9%, <em>P</em><0.05) and lipoprotein(a) (-37.0%, <em>P</em><0.05) and increased nitric oxide level (62.2%, <em>P</em><0.05). In addition, the levels of these variables were positively correlated with change in 16,17-EDP and EEQs content but negatively with change in PGJ2 content.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>ω-3 PUFA supplementation may improve lipid metabolism and endothelial function possibly by affecting eicosanoid metabolic status at a systemic level during convalescent healing after AMI.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Clinical trial registration</h3><p>URL: <a href="http://www.chictr.org.cn/">http://www.chictr.org.cn</a>. Unique identifier: ChiCTR1900025859.</p>
nutrition & dietetics